Form 8-K - Current report:
SEC Accession No. 0001178913-25-002570
Filing Date
2025-08-01
Accepted
2025-08-01 12:29:24
Documents
16
Period of Report
2025-08-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K zk2533522.htm   iXBRL 8-K 77620
2 EXHIBIT 10.1 exhibit_10-1.htm EX-10.1 52841
3 EXHIBIT 10.2 exhibit_10-2.htm EX-10.2 117245
4 exhibit_10-3.htm EX-10.3 103816
  Complete submission text file 0001178913-25-002570.txt   605933

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA slxn-20250801.xsd EX-101.SCH 4627
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE slxn-20250801_def.xml EX-101.DEF 18273
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE slxn-20250801_lab.xml EX-101.LAB 27771
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE slxn-20250801_pre.xml EX-101.PRE 20515
19 EXTRACTED XBRL INSTANCE DOCUMENT zk2533522_htm.xml XML 6564
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42253 | Film No.: 251175029
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)